

Correction

Correction: Moeker, N.; et al. Antibody Selection for Cancer Target Validation of FSH-Receptor in Immunohistochemical Settings. *Antibodies* 2017, 6, 15

Nina Möker¹, Solveig Peters¹, Robert Rauchenberger¹, Nicolae Ghinea², Christian Kunz¹ and *Antibodies* Editorial Office^{3,*}

¹ MorphoSys AG, Discovery Alliance and Technologies, 82152 Planegg, Bavaria, Germany; moekern@gmail.com (N.M.); Solveig.Peters@morphosys.com (S.P.); robert.rauchenberger@online.de (R.R.); Christian.Kunz@morphosys.com (C.K.)

² Curie Institute, Inserm-Tumoral Angiogenesis Unit, Translational Research Department, Curie Hospital, 75005-Paris, France; nicolae.ghinea@curie.fr

³ MDPI, St. Alban-Anlage 66, 4052 Basel, Switzerland

* Correspondence: antibodies@mdpi.com

Received: 20 August 2018; Accepted: 22 August 2018; Published: 24 August 2018



The authors wish to make the following correction to the Conflict of Interests section in their published paper [1]:

“Christian Kunz and Solveig Peters are employees and Nina Möker and Robert Rauchenberger are former employees of MorphoSys AG, which owns the Ylanthia antibodies described in the publication.”
The manuscript will be updated and the original will remain online on the article webpage.

Reference

1. Moeker, N.; Peters, S.; Rauchenberger, R.; Ghinea, N.; Kunz, C. Antibody Selection for Cancer Target Validation of FSH-Receptor in Immunohistochemical Settings. *Antibodies* 2017, 6, 15. [[CrossRef](#)]



© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<http://creativecommons.org/licenses/by/4.0/>).